The role of cholesterol in prostatic diseases

Urological Science

Volumn 22, Issue 3, 2011, Pages 97-102

  Tong, Yat Ching ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Benign prostatic hyperplasia; Cholesterol; Lipid raft; Men's health; Prostate; Prostatic cancer

Indexed keywords

CANDICIDIN; CAVEOLIN 1; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CHOLESTEROL METABOLISM; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIPID RAFT; LOWER URINARY TRACT SYMPTOM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; TREATMENT OUTCOME;

EID: 82455179438     PISSN: 18795226     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urols.2011.08.002     Document Type: Review

References (65)

1. White R.M. On the occurrence of crystals in tumours. J Pathol Bacteriol 1909, 13:3-10.
2. Swyer G. The cholesterol content of normal and enlarged prostates. Cancer Res 1942, 2:372-375.
3. Freeman M.R., Solomon K.R. Cholesterol and prostate cancer. J Cell Biochem 2004, 91:54-69.
4. Cook L.S., Goldoft M., Schwartz S.M., Weiss N.S. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999, 161:152-155.
5. Yang C.R., Ou Y.C., Ho H.C., Kao Y.L., Cheng C.L., Chen J.T., et al. Unsuspected prostate carcinoma and prostatic intraepithelial neoplasm in Taiwanese patients undergoing cystoprostatectomy. Mol Urol 1999, 3:33-39.
6. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388-2394.
7. Shannon J., Tewoderos S., Garzotto M., Beer T.M., Derenick R., Palma A., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162:318-325.
8. Hammarsten J., Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999, 8:29-36.
9. Rohrmann S., Smit E., Giovannucci E., Platz E.A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes Relat Metab Disord 2005, 29:310-316.
10. Di Vizio D., Solomon K.R., Freeman M.R. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori 2008, 94:633-639.
11. Schaffner C.P. Prostatic cholesterol metabolism: regulation and alteration. Progr Clin Biol Res 1981, 75A:279-324.
12. Simons K., Ikonen E. How cells handle cholesterol. Science 2000, 290:1721-1726.
13. McGrother C.W., Donaldson M.M., Hayward T., Matthews R., Dallosso H.M., Hyde C. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006, 35:16-24.
14. Mydlo J.H. The impact of obesity in urology. Urol Clin North Am 2004, 31:275-287.
15. Dallosso H.M., McGrother C.W., Matthews R.J., Donaldson M.M. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 2003, 92:69-77.
16. Rohrmann S., De Marzo A.M., Smit E., Giovannucci E., Platz E.A. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005, 62:27-33.
17. Hammarsten J., Hogstedt B. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002, 36:330-338.
18. Cheng J.T., Tong Y.C. Alterations of nerve-growth factor and p75(NTR) expressions in urinary bladder of fructose-fed obese rats. Neurosci Lett 2008, 441:25-28.
19. Tong Y.C., Cheng J.T. Alterations of M2,3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J Urol 2007, 178:1537-1542.
20. Vikram A., Jena G.B., Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010, 70:79-89.
21. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991, 63:963-966.
22. Yatani R., Shiraishi T., Nakakuki K., Kusano I., Takanari H., Hayashi T., et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst 1988, 80:683-687.
23. Pienta K.J. The epidemiology of prostate cancer: clues for chemoprevention. In Vivo 1994, 8:419-422.
24. Michaud D.S., Augustsson K., Rimm E.B., Stampfer M.J., Willet W.C., Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001, 12:557-567.
25. Veierod M.B., Laake P., Thelle D.S. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997, 73:634-638.
26. Wu Y., Zheng W., Sellers T.A., Kushi L.H., Bostick R.M., Potter J.D. Dietary cholesterol, fat, and lung cancer incidence among older women: the Iowa Women's Health Study (United States). Cancer Causes Control 1994, 5:395-400.
27. Chen H., Ward M.H., Tucker K.L., Graubard B.I., McComb R.D., Potischman N.A., et al. Diet and risk of adult glioma in eastern Nebraska, United States. Cancer Causes Control 2002, 13:647-655.
28. Smith-Warner S.A., Ritz J., Hunter D.J., Albanes D., Beeson W.L., van den Brandt P.A., et al. Dietary fat and risk of lung cancer in a pooled analysis of prospective studies. Cancer Epidemiol Biomarkers Prev 2002, 11:987-992.
29. De Stefani E., Mendilaharsu M., Deneo-Pellegrini H., Ronco A. Influence of dietary levels of fat, cholesterol, and calcium on colorectal cancer. Nutr Cancer 1997, 29:83-89.
30. Horn-Ross P.L., Morrow M., Ljung B.M. Diet and the risk of salivary gland cancer. Am J Epidemiol 1997, 146:171-176.
31. Jarvinen R., Knekt P., Hakulinen T., Rissanen H., Heliovaara M. Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 2001, 85:357-361.
32. Kaplan S., Novikov I., Modan B. Nutritional factors in the etiology of brain tumors: potential role of nitrosamines, fat, and cholesterol. Am J Epidemiol 1997, 146:832-841.
33. Umeki S. Decreases in serum cholesterol levels in advanced lung cancer. Respiration 1993, 60:178-181.
34. Eichholzer M., Stahelin H.B., Gutzwiller F., Ludin E., Bernasconi F. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 2000, 71:569-574.
35. Knekt P., Reunanen A., Aromaa A., Heliovaara M., Hakulinen T., Hakama M. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 1988, 41:519-530.
36. Wald N.J., Thompson S.G., Law M.R., Densem J.W., Bailey A. Serum cholesterol and subsequent risk of cancer: results from the BUPA study. Br J Cancer 1989, 59:936-938.
37. Waters D.D. What do the statin trials tell us?. Clin Cardiol 2001, 24(8 Suppl):1113-1117.
38. Blais L., Desgagne A., LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000, 160:2363-2368.
39. Pedersen T.R., Wilhelmsen L., Faergeman O., Strandberg T.E., Thorgeirsson G., Troedsson L., et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000, 86:257-262.
40. Graziani S.R., Igreja F.A., Hegg R., Meneghetti C., Brandizzi L.I., Barboza R., et al. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol 2002, 85:493-497.
41. Tatidis L., Masquelier M., Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem Pharmacol 2002, 63:2169-2180.
42. Caruso M.G., Notarnicola M., Santillo M., Cavallini A., Di Leo A. Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res. 1999, 19:451-454.
43. Caruso M.G., Notarnicola M., Cavallini A., Di Leo A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. J Gastroenterol 2002, 37:504-508.
44. Heemers H., Maes B., Foufelle F., Heyns W., Verhoeven G., Swinnen J.V. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 2001, 15:1817-1828.
45. Flavin R., Zadra G., Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011, 223:283-294.
46. Thysell E., Surowiec I., Hornberg E., Crnalic S., Widmark A., Johansson A.I., et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 2010, 5:e14175.
47. Gordon H.W., Schaffner C.P. The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia. Proc Natl Acad Sci U S A 1968, 60:1201-1208.
48. Schaffner C.P., Gordon H.W. The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci U S A 1968, 61:36-41.
49. Keshin J.G. Effect of candicidin on the human benign hypertrophied prostate gland. Int Surg 1973, 58:116-122.
50. Orkin L.A. Efficacy of candicidin in benign prostatic hypertrophy. Urology 1974, 4:80-84.
51. Ukomadu C., Dutta A. Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 2003, 278:4840-4846.
52. Alonso D.F., Farina H.G., Skilton G., Gabri M.R., De Lorenzo M.S., Gomez D.E. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998, 50:83-93.
53. Wong W.W., Tan M.M., Xia Z., Dimitroulakos J., Minden M.D., Penn L.Z. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001, 7:2067-2075.
54. Wachtershauser A., Akoglu B., Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001, 22:1061-1067.
55. Mondul A.M., Clipp S.L., Helzlsouer K.J., Platz E.A. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 2010, 21:61-68.
56. Pike L.J. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res 2006, 47:1597-1598.
57. Katagiri Y.U., Kiyokawa N., Fujimoto J. A role for lipid rafts in immune cell signaling. Microbiol Immunol 2001, 45:1-8.
58. Harder T., Scheiffele P., Verkade P., Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 1998, 141:929-942.
59. van Deurs B., Roepstorff K., Hommelgaard A.M., Sandvig K. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 2003, 13:92-100.
60. Li S., Couet J., Lisanti M.P. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996, 271:29182-29190.
61. Solomon K.R., Rudd C.E., Finberg R.W. The association between glycosylphosphatidylinositol-anchored proteins and heterotrimeric G protein alpha subunits in lymphocytes. Proc Natl Acad Sci U S A 1996, 93:6053-6058.
62. Tahir S.A., Yang G., Ebara S., Timme T.L., Satoh T., Li L., et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001, 61:3882-3885.
63. Yang G., Truong L.D., Wheeler T.M., Thompson T.C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999, 59:5719-5723.
64. Satoh T., Yang G., Egawa S., Addai J., Frolov A., Kuwao S., et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003, 97:1225-1233.
65. Lu M.L., Schneider M.C., Zheng Y., Zhang X., Richie J.P. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001, 276:13442-13451.